M&A deals, company strategies, pipeline updates and more
Follow our coverage of the 2019 J.P. Morgan Healthcare Conference in San Francisco
Novavax's NanoFlu vaccine beat Sanofi's Fluzone HD in seniors in a midstage test, setting up the smaller company's shot for a move into phase 3.
Here is some other vaccine news of note for the week.
To make sense of Sanofi's Dengvaxia experiences, look no further than the old adage: Learn from your mistakes.
Instead of launching their new combination pediatric shot now, Sanofi and Merck will spend this year building up supplies for a 2020 rollout.
The FDA fast-tracked Valneva's shot against chikungunya, a disease with no approved vaccines.
As tests by Hong Kong's health department and Sanofi showed no quality problems, Sanofi's Vaxigrip has been cleared for use.
Since GSK pulled LYMErix in 2002, there's been no FDA-approved Lyme shot, and Valneva's VLA15 is the only active clinical program.
After a horrible flu season last year, more people have gotten vaccinations so far this year, according to the CDC.